ASH 2021 | Phase III INDEPENDENCE trial of luspatercept in patients with TD myelofibrosis on JAKi therapy
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, talks on the rationale and study design of the currently enrolling Phase III INDEPENDENCE trial (NCT04717414) evaluating the safety and efficacy of luspatercept for the treatment of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF). The randomized, double-blinded trial will compare luspatercept to placebo as an add on to JAK inhibitor (JAKi) therapy in patients requiring regular red blood cell transfusions. Treatment options for anemia associated with transfusion-dependent (TD) MF are an unmet need, so the outcome of the INDEPENDENCE trial has the potential to change clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
